Monday Feb 10, 2014 Conrad Duke of Windsor

First Page		Document Content
Date: 2014-03-26 15:05:14 Regulus Therapeutics Gilead Sciences		Monday Feb 10, 2014 Conrad Duke of Windsor Add to Reading List Source URL: www.bio.org Download Document from Source Website File Size: 587,76 KB Share Document on Facebook

	Analysis from the makers of and DocID: 1ad5L - View Document
	Breakthrough for treatment of cancer, and other diseases InteRNA Technologies BV is a Utrecht based biotech company that is developing new therapeutics for cancer and other diseases. The approach is based on science deve DocID: 178Ot - View Document
	Breast cancer and microRNA Fumiaki Sato, MD, PhD. Associate Professor Department of Breast Surgery, Graduate School of Medicine, Kyoto University. MicroRNA is a species of short[removed]nts) non-coding RNA, which regulate DocID: 10ALg - View Document
	January 13, 2014 Alnylam and Genzyme Form Transformational Alliance for RNAi Therapeutics as Genetic Medicines - New Collaboration Expected to Accelerate and Expand Global Product Value for RNAi Therapeutic Genetic Medi DocID: R6Rq - View Document
	Microsoft Word - Earnings release - final for release.doc DocID: tJRx - View Document